An observational study in Myocardial Infarction, sponsored by North Estonia Medical Centre. Completed at 1 site in Estonia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by North Estonia Medical Centre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Myocardial Infarction with a site in Estonia — 1 open to participants now, 3 under way, 2 of them phase 3. Myocardial Infarction · Estonia.
Among the 11 studies in Myocardial Infarction with a site in Estonia, this one is the only one that started in 2024, is one of 2 observational ones, and was the 11th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →1 of the 11 studies in Myocardial Infarction with a site in Estonia is open now. Recruiting first, the newest first:
Viatris Innovation GmbH · Sites in Estonia, United States, Australia and 44 more countries
Ages 18+
A study can be open while its sites in Estonia have not opened yet or have stopped. Only those recruiting at a site in Estonia →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 5,081 across the 9 interventional studies, 619 across the 2 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 10 most frequent:
North Estonia Medical Centre is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
North Estonia Medical Centre has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies in Myocardial Infarction with a site in Estonia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Myocardial Infarction with a site in Estonia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This retrospective substudy describes low-density lipoprotein cholesterol (LDL-C) changes and treatment-target attainment among patients with previous myocardial infarction who participated in the AIDAVA first-generation (G1) prototype evaluation in Estonia, Austria and the Netherlands. Existing study data and clinical records are analysed. The LDL-C research question was developed after the original evaluation was planned and was not its prespecified efficacy endpoint. No additional intervention, treatment assignment, visit or blood sampling is introduced by this substudy. Findings are exploratory and cannot establish a causal effect of AIDAVA participation.
AIDAVA developed an AI-assisted system for integrating, curating and reusing personal health data. The original evaluation addressed technical performance, usability and acceptance. Cardiovascular participants contributed existing clinical records and longitudinal data, including home blood-pressure measurements, with support from study nurses and data curators. The cardiovascular protocol also envisaged automatic SMART risk-score assessment.
This registration covers only the secondary LDL-C analysis of the G1 post-myocardial infarction cohort. It does not register the full AIDAVA project, breast-cancer evaluation or G2 prototype evaluation. The original evaluation was not registered. This summary was prepared after the LDL-C analysis and does not represent prospective specification of its hypotheses, outcomes or analysis methods.
The criteria were revised on the registry on Sep 25, 2026. See what changed
Adults from the AIDAVA G1 cardiovascular cohort at North Estonia Medical Centre, Tallinn; Medical University of Graz, Graz; and Maastricht University Medical Centre+, Maastricht, with a documented history of type 1 myocardial infarction and permission for the relevant secondary use of their data.
The source cohort comprised digitally active adults with available medical data, smartphone ownership/use, a confirmed symptomatic type 1 myocardial infarction and written informed consent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous participation in two-week G1 health-data curation and prototype testing with nurse/curator guidance, and home blood-pressure data collection. These activities occurred in the original evaluation; no exposure is assigned in this retrospective substudy.
Percentage of participants with LDL-C below 1.8 mmol/L at follow-up.
Time frame: Day 365
Percentage of participants with LDL-C below 1.4 mmol/L at follow-up.
Time frame: Day 365
Plan to share: No — As per the Ethics Committee approval
Ran from Jul 2024 to primary completion in Jun 2026, 23 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
North Estonia Medical Centre